Thus, our primary goal in this proof-of-principle initial study was to determine if a combined TMEM-MenaCalc biomarker is able to improve upon the prognostication ability of either marker alone, all within a small cohort of patients with HR+/HER2− breast cancer (see Section 4 Materials and Methods for cohort description). The gene discussed is HR; the disease is breast carcinoma.